Surgery Augments Survival in Patients with Primary Intestinal Diffuse Large B-cell Lymphoma

Surgery is effective for patients with primary intestinal diffuse large B-cell lymphoma (PI-DLBCL), according to a study published in Cancer Medicine.

“The clinical characteristics and prognosis of primary intestinal diffuse large B-cell lymphoma (PI-DLBCL) are rarely reported. We aimed to explore the role of surgery in patients with PI-DLBCL,” the researchers wrote.

To conduct this study, researchers assessed just over 1,600 patients with PI-DLBCL from the Surveillance, Epidemiology, and End Results database. They evaluated the efficacy of surgery using Kaplan-Meier and Cox proportional regression, and Lasso regression to determine independent risk factors of overall survival (OS).

Following analysis, the results showed that surgery markedly improved survival, as shown in both univariate and multivariate analyses (P=0.007, P<0.001, respectively).

“This study approves the beneficial effect of surgery on clinical endpoints in PI-DLBCL patients. For those who are not suitable for resection, local tumor destruction may also be a practical option,” the researchers concluded. They added that the “predictive nomogram and the web-based calculator could help clinicians individually evaluate the prognosis and optimize personalized treatment decisions for these patients.”